Protocol DUR001-106: A Phase 1, Open Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dalbavancin in Hospitalized Children Aged 3 months to 11 years receiving Standard Intravenous...

Project: Research project

Project Details

StatusFinished
Effective start/end date6/24/1312/31/14

Funding

  • Duke University
  • Durata Therapeutics International B.V.